Lurasidone for the treatment of schizophrenia in paediatric patients - Trial 2013-001523-39

Name: Clinical Trial 2013-001523-39
Creator: Sunovion Pharmaceuticals Inc.
Keywords: schizophrenia, clinical trial

Access comprehensive clinical trial information for 2013-001523-39 through Pure Global AI's free database. This phase not specified trial is sponsored by Sunovion Pharmaceuticals Inc. and is currently status unknown. The study focuses on schizophrenia.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2013-001523-39

Trial Details

EU Clinical Trials Register • 2013-001523-39

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Lurasidone for the treatment of schizophrenia in paediatric patients

Study Focus

Disease/Condition

schizophrenia

Sponsor & Location

Primary Sponsor

Sunovion Pharmaceuticals Inc.

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

1. Clinically significant neurological, metabolic (including type 1 diabetes), hepatic, renal,

ICD-10 Classifications

Acute schizophrenia-like psychotic disorder

Schizophrenia

Residual schizophrenia

Schizophrenia, unspecified

Acute and transient psychotic disorders

Data Source

Registry

EU Clinical Trials Register

Trial ID

2013-001523-39

Type

Non-Device Trial